Intellia Therapeutics (NTLA) Tax Provisions (2015)

Intellia Therapeutics (NTLA) reported Tax Provisions of -$246000.0 for Q4 2015, up 12.77% quarter-over-quarter from -$282000.0 in Q3 2015.

Intellia Therapeutics (NTLA) Tax Provisions (2015) Analysis & Trends

Intellia Therapeutics (NTLA) has 1 years of Tax Provisions data on file, last reported at -$246000.0 in Q4 2015.

Tax Provisions for Q4 2015 came in at -$246000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2016 was -$246000.0 (changed N/A YoY), and the FY2015 annual result was -$1.0 million, changed N/A from the prior year.
Tax Provisions grew to -$246000.0 in Q4 2015 per NTLA's latest filing, from -$282000.0 in the prior quarter.
Over five years, Tax Provisions peaked at -$102000.0 in Q1 2015 and troughed at -$382000.0 in Q2 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-11.20 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	216,000.00
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-859,000.00
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	221.50 Mn
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Intellia Therapeutics	1.86 Bn	1.86 Bn	-	-

Download Data